It's IPO day for J&J's Kenvue: Stock gains 20% in first day of trading as unit raises $3.8B

Drew Armstrong

Executive Editor

Nicole DeFeudis

Editor

In one of the biggest healthcare IPOs of the last decade, Johnson & Johnson’s consumer spinout Kenvue raised $3.8 billion and started trading on the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

It's IPO day for J&J's Kenvue: Stock gains 20% in first day of trading as unit raises $3.8B

Drew Armstrong

Executive Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

It's IPO day for J&J's Ken­vue: Stock gains 20% in first day of trad­ing as unit rais­es $3.8B

Executive Editor

Editor

Sign up to read this article for free.

It's IPO day for J&J's Kenvue: Stock gains 20% in first day of trading as unit raises $3.8B